Shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $42.85 and last traded at $43.23, with a volume of 74,719 shares. The stock had previously closed at $37.44.

Separately, ValuEngine upgraded shares of Opiant Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday.

The stock has a 50 day moving average of $21.49 and a 200-day moving average of $10.66. The stock has a market cap of $102.31 million, a price-to-earnings ratio of 18.99 and a beta of -0.75.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Wednesday, June 14th. The technology company reported ($1.55) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.73. Opiant Pharmaceuticals had a net margin of 38.89% and a return on equity of 5,686.82%. The firm had revenue of $0.02 million for the quarter. On average, equities analysts anticipate that Opiant Pharmaceuticals, Inc. will post $0.50 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Opiant Pharmaceuticals, Inc. (OPNT) Hits New 52-Week High at $42.85” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.